²é¿´: 484  |  »Ø¸´: 2
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

hansom999

Òø³æ (СÓÐÃûÆø)

[½»Á÷] Ö¬·¾×éÖ¯Ô´»ùÖÊϸ°û£¨ADSCs):ϸ°ûѧ¹¤³ÌµÄÐÂÑ¡Ôñ

Ŀǰ£¬³ÉÌå¸Éϸ°ûÔÚ×éÖ¯ÔÙÉúºÍÐÞ¸´µÄÑо¿Öеõ½¹ã·ºÓ¦Ó㬸Éϸ°ûÒÆÖ²ÖÎÁƼ±ÐÔ
Ð£ËÀÒ²³ÉΪ½üÄêÀ´Ñо¿µÄÈȵ㡣ÓÃÓÚ»ù´¡ºÍÁÙ´²Ñо¿µÄ¸Éϸ°ûÖ÷ÒªÓÐÅßÌ¥¸Éϸ
°û¡¢¹Ç÷À¼¡ÎÀÐÇϸ°û¡¢¹ÇËè¼ä³äÖʸÉϸ°ûµÈ[1¡«3]£¬Ñо¿Ö¤Ã÷ͨ¹ýÒÆÖ²ÕâЩ¸Éϸ°û
¿ÉÒÔ¼õÉÙ¹£ËÀÃæ»ý£¬¸ÄÉÆÐļ¡ÖØËÜ£¬´Ó¶ø¸ÄÉÆÐÄÔ๦ÄÜ[4]¡£ÅßÌ¥¸Éϸ°ûÖ»ÄܽøÐÐÒì
ÌåÒÆÖ²£¬À´Ô´À§ÄÑ£¬²»½ö´æÔÚÃâÒßÅųâµÄÎÊÌ⣬»¹Éæ¼°µ½Â×ÀíѧµÄÎÊÌâ¡£¹Ç÷À¼¡ÎÀ
ÐÇϸ°ûºÍ¹ÇËè¸Éϸ°ûÊôÓÚ³ÉÌå¶àÄܸÉϸ°û£¬¿ÉÒÔ½øÐÐ×ÔÌåÒÆÖ²£¬±ÜÃâÁËÉÏÊöÎÊÌ⣬
µ«×ÔÌå¹Ç÷À¼¡ÎÀÐÇϸ°ûÈ¡²ÄÀ§ÄÑ£¬Ä¿Ç°Ñо¿¼°Ó¦Óý϶àµÄÊǹÇËèÀ´Ô´¸Éϸ°û¡£µ«¹Ç
ËèÀ´Ô´¸Éϸ°ûÒ²´æÔÚÀ´Ô´²»×㣬ȡ²ÄÀ§ÄÑ,¸ø»¼Õß´øÀ´½Ï¶àÍ´¿àËùÒÔ½ÏÄÑΪÈËÃÇËù½Ó
ÊܵÈȱµã£¬Òò´ËÐèҪѰÕÒÒ»ÖÖеĸüÒ×±»»¼Õß½ÓÊܵĸÉϸ°ûÀ´Ô´¡£Ö¬·¾×é֯ͬ¹ÇËè
Ò»Ñù£¬Ò²´ÓÖÐÅß²ã·Ö»¯·¢Óý¶øÀ´£¬²¢º¬ÓдóÁ¿µÄÒ×·ÖÀëµÄÖ§³Öϸ°û¡£2001Ä꣬ZUK[
5]µÈ´ÓÈ˵ÄÖ¬·¾×éÖ¯Öгɹ¦·ÖÀë³ö¾ßÓжàÏò·Ö»¯Ç±ÄܵĻùÖÊϸ°û£¨Adipose tissue
-derived stromal cells, ADSCs£©£¬ÓëÆäËü³ÉÌå¸Éϸ°ûÏà±È£¬Ö¬·¾À´Ô´µÄ»ùÖÊϸ°û
È¡²Ä¸ü·½±ã£¬¸üÈÝÒ×»ñÈ¡¡£ÕâÒ»·¢ÏÖΪ¸Éϸ°ûµÄÀ´Ô´ÌṩÁËеÄÑ¡Ôñ¡£

1  ADSCµÄÃüÃû

      ADSCÔÚÒÔÍùÑо¿Öнз¨²»¾¡Ïàͬ£¬ÓеijÆÎªPLA(processed lipoaspirate c
ells)[5,6], ÓеijÆÖ®ÎªÖ¬·¾À´Ô´¸Éϸ°û£¨adipose-derived stem cells£©[7]¡¢Ö¬
·¾À´Ô´»ùÖÊϸ°û£¨adipose-derived stromal cells, ADSC£©[8] ¡¢Ö¬·¾À´Ô´¼ä³äÖÊ
£¨¸É£©Ï¸°û£¨adipose-derived mesenchymal/stem cells£©[9,10]¡¢Ö¬·¾À´Ô´³ÉÌå
¸Éϸ°û£¨Adipose-derived adult stem cells£©[11]£¬»¹ÓеijÆÎªÇ°Ö¬·¾Ï¸°û[12]
£¨preadipocyte£©, ÆäʵÖÊÉÏÒ²ÊÇÕâȺϸ°û¡£ÕâЩ²»Í¬µÄ½Ð·¨ËµÃ÷¶ÔÕâȺϸ°ûÉÐȱ
·¦×ã¹»µÄÁ˽âºÍͳһµÄÈÏʶ£¬Èç¶Ôϸ°ûµÄÆðÔ´¡¢±íÐÍ¡¢¹¦ÄÜ·Ö»¯µÈµÈ¡£¶øADSCÔ½À´
Ô½±»ÈËÃÇËù½ÓÊÜ£¬ÒòΪÕâÒ»½Ð·¨¸üÄÜ·´Ó³³ö¸Ãϸ°ûµÄÀ´Ô´ºÍÌØÐÔ[13]¡£

2   ADSCµÄ»ñÈ¡

      ADSCÓëMSC Ò»Ñù£¬ÔÚÍâÐÎÉϱíÏÖËÆ³ÉÏËάϸ°û¡£¶øÇÒ£¬ADSCÔÚÆ¤ÏÂÖ¬·¾ÖеÄ
º¬Á¿ÊÇÊ®·Ö·á¸»µÄ¡£Óë¹ÇËèÀ´Ô´¼ä³äÖʸÉϸ°ûÏà±È£¬ADSCµÄÌáÈ¡¸ü·½±ã¡£¹ÇËè¼ä³ä
ÖʸÉϸ°ûÖ»ÊǹÇËèµ¥¸öºËϸ°ûȺÖеļ«Ð¡Ò»²¿·Ö¡£Í¨³£Í¨¹ýÂé×íϳéÈ¡¹ÇË裬²ÉÓÃ
·Ö²ãÀëÎöµÄ·½·¨»ñÈ¡¹ÇËè±³µ¥¸öºËϸ°ûȺ£¬¶øµ¥¸öºËϸ°ûȺÖоø´ó²¿·ÖÊÇÔìѪ¸Éϸ
°û£¬¶øÍ¨¹ýÅàÑøÆ¿Ìù±Úɸѡºó£¬¹ÇËè¼ä³äÖʸÉϸ°ûÖ»Õ¼Ìù±Úϸ°ûµÄ0.001%[5]¡£¶øA
DSCµÄÌáÈ¡Ïà¶Ô¸üÈÝÒ×£¬Á¿¸ü¶à¡£Zuk[6]µÈÓ¦ÓÃÕæ¿Õ³éÎü¼¼Êõ´ÓÈËÆ¤Ï³éȡ֬·¾£¬Í¨
¹ýIÐͽºÔ­Ã¸Ïû»¯Ìù±ÚµÄ·½·¨¹²´Ó300 mlÎü³ö×éÖ¯ÖлñµÃ£¨2¡«6£©¡Á108¸ö³ÉÏËάϸ
°ûÑùϸ°û£¬ÓÃÁ÷ʽϸ°û¼¼Êõ¼ì²â»ñµÃµÄϸ°û±íÃæASO2£¨¼ä³äÖÊÀ´Ô´Ï¸°ûÌØÒìÐÔ¿¹Ô­
£©±íÃ÷¾ø´ó¶àÊýϸ°û£¨85%¡À12.8%£©Îª¼ä³äÖÊÀ´Ô´µÄϸ°û£¬½öÓÐÉÙÁ¿µÄÍâÆ¤Ï¸°û¡¢
ÄÚÆ¤Ï¸°ûºÍƽ»¬¼¡Ï¸°û¡£Ö¬·¾Ç°Ìåϸ°û£¨¿É½øÒ»²½·ÖÁѲ¢·Ö»¯ÎªÖ¬·¾£©Ò²½öÕ¼0.02
%¡£Ò²¾ÍÊÇ˵£¬´Ó1 ml³éÎü×éÖ¯¿ÉÒÔ»ñµÃµÄϸ°ûÊýÁ¿¼¶ÔÚ105¡£ÎÒÃǵÄÑо¿£¨ÉÐδ·¢
±í£©±È½ÏÁËÈ®µÄƤÏÂÖ¬·¾ºÍ¹ÇËèÌáÈ¡¸Éϸ°ûµÄÄÜÁ¦Ò²·¢ÏÖ£¬Ã¿¿ËÖ¬·¾¿É»ñÈ¡µÄÌù±Ú
µÄÔ­´ú»ùÖÊϸ°ûÊýÔÚ106¸ö×óÓÒ£»¶ø¹ÇËèͨ¹ýÌݶȷֲãÀëÐĵķ½·¨»ñµÃµÄµ¥¸öºËϸ°û
ȺԼÿºÁÉý£¨0.5¡«1£©¡Á107¡£Èç¹û¿¼Âǵ½¹ÇËè¼ä³äÖʸÉϸ°ûÖ»Õ¼ÆäÖеÄ0.001%¡«0
.01%£¬ÔòÿºÁÉý¹ÇËèÖ»¿É»ñµÃ102¡«103ÊýÁ¿¼¶µÄMSC¡£¶øÇÒÔÚÌåÍâ½øÐÐÅàÑøÀ©Ôö£¬A
DSC¶ÔÅàÑø»ùûÓÐÌØÊâÒªÇó£¬À©ÔöѸËÙ£¬¾­¶à´ú´«ÅàÑø£¬±¶Ôöʱ¼ä±£³ÖÎȶ¨£¨Ô¼60
h£©¡£AILHAUD  GERARDÉêÇëµÄÃÀ¹úרÀûUS2004229351[14]³Æ£¬´Ó³ÉÈËÖ¬·¾×éÖ¯ÖзÖ
ÀëµÃµ½µÄ¶àÄܸÉϸ°û£¬¾ßÓжËÁ£Ã¸»îÐÔ¡¢HLA ¢ñÒõÐÔ±íÐÍ£¨Á÷ʽϸ°ûÒǼì²â£©¡¢Õý
³£È¾É«Ìå×é¡¢¾ßÓÐÖÁÉÙ130´ú·ÖÁÑÔöÖ³µÄ×ÔÎÒ¸üÐÂÄÜÁ¦¡£¶øÇÒÖ¬·¾×éÖ¯º¬Á¿·á¸»,Ô¶
´óÓÚ¹ÇËè×éÖ¯,Òò¶øÓпÉÄÜ´ÓÖ¬·¾×éÖ¯ÖзÖÀë³ö³ä×ãµÄ»ùÖʸÉϸ°û,²»¾­¹ýÅàÑø¶øÖ±
½ÓÓÃÓÚϸ°ûÒÆÖ²ÖÎÁÆ¡£

3 ADSCµÄ¼ø¶¨

     ADSCÓë¹ÇËè¼ä³äÖʸÉϸ°ûÊ®·ÖÏàËÆ£¬¶þÕß¶¼´ú±íÁËͨ¹ýÅàÑøÆ¿ÄÚÕ³¸½·¨´ÓÖ¬·¾
¿âÖзÖÀëµÄ»ùÖÊϸ°û²¿·Ö£¬Ö»²»¹ýǰÕßÊÇÀ´Ô´ÓÚÆ¤ÏÂÖ¬·¾£¬ºóÕßÀ´Ô´ÓÚ¹ÇËèÖ¬·¾¡£
¶þÕßµÄϸ°û±íÃæ¿¹Ô­±êÖ¾Ò²´ó²¿·ÖÏàͬ£¬½öÓкÜС²îÒì¡£Gronthos  S[15]µÈÑо¿·¢
ÏÖ£¬È˵ÄADSCÓë¹ÇËè¼ä³äÖʸÉϸ°û±íÃæ±êÖ¾CD9£¬CD10£¬CD13£¬CD29,CD34£¬CD44£¬
CD49(d)£¬CD49(e)£¬CD54£¬CD55£¬CD59£¬CD105£¬CD146ºÍCD166Ïàͬ£»De Ugarte D
A[16]µÈÈËÑо¿ÁË5ÀýÖ¬·¾³éÎüÊõ»¼ÕßÀ´Ô´µÄ¹ÇËè¼ä³äÖʸÉϸ°ûºÍÖ¬·¾¸Éϸ°û±íÃæÏÔ
ÐÍ¡£½«PLAÖ¬·¾Ï¸°ûºÍBM-MSC·ÖÀë¡¢´«´ú£¬È»ºóͨ¹ýÁ÷ʽϸ°ûÒǼø¶¨ÁËϸ°û±íÃæ±êÖ¾
¡£PLAºÍBM-MSCϸ°û¾ù±í´ïCD13, CD29£¬CD44£¬CD90£¬CD105£¬SH-3ºÍSTRO-1£¬¶øÏ¸
°ûÕ³¸½·Ö×ÓCD49d(Õ³ºÏËØ-¦Á4),CD54(ICAM-1),CD34ºÍCD106 (VCAM-1)µÄ±í´ï²»Í¬¡£
ÕâЩ²»Í¬µÄϸ°ûÕ³¸½·Ö×ÓÓëÔìѪ¸Éϸ°ûµÄ¹é³²¡¢¶¯Ô±ºÍÔöÖ³Óйء£NakagamiµÈ[17]
Ñо¿C57B1/6СÊóÒ²·¢ÏÖADSC±í´ïSca1(ly-6A/E)£¨¸Éϸ°û¿¹Ô­ly-6A/E£¬Ð¡ÊóÔìѪ¸É
ϸ°û±êÖ¾·Ö×Ó£©ºÍCD44¿¹Ô­£¬µ«²»±í´ï c-kit(СÊó¶àÄܸÉϸ°û±íÃæÑôÐÔ·Ö×Ó±êÖ¾Ö®
Ò»)£¬Lin(СÊó¶àÄܸÉϸ°û±íÃæÒõÐÔ·Ö×Ó±êÖ¾)£¬CD11 b£¬CD31£¬CD34£¬CD45¡£¶øÇÒ
£¬ÕâЩϸ°û±íÃæ±êÖ¾Ëæ¶à´Î´«´úÅàÑø±í´ïÎȶ¨¡£ÎÒÃǶԴóÊóµÄADSCµÄÑо¿·¢ÏÖ£¬Ï¸
°ûÁ¬Ðø´«´ú11´ú£¬Ï¸°û±íÃæ±ê¼ÇÎ޸ı䡣

      ´ÓÒÔÉÏÑо¿·¢ÏÖ£¬²»Í¬µÄÑо¿¶ÔÓÚ±íÃæ±êÖ¾CD34ÊÇ·ñÑôÐÔ½á¹û²»Í¬¡£ÓÐÑо¿
[18]·¢ÏÖзÖÀëδ½Ó´¥ÅàÑøÆ¿µÄADSCÓë¾­ÅàÑøÆ¿ÅàÑøºóµÄADSCϸ°û±íÃæ±êÖ¾·¢ÉúÃ÷
ÏԱ仯£ºÐÂÏÊ·ÖÀëµÄADSCÖÐ90%ÒÔÉÏCD34ÑôÐÔ±í´ï£¬µ«¾­3ÖÁ5ÌìÌåÍâÅàÑøºó±í´ïÃ÷ÏÔ
¼õÉÙ¡£Õâ¿ÉÄÜ¿ÉÒÔ½âÊÍÒÔÍù²»Í¬µÄÑо¿½á¹û¡£

4  ADSCµÄ¶àϵ·Ö»¯ÄÜÁ¦

      µ¥´Óϸ°û±íÃæ±êÖ¾ÊÇÎÞ·¨¼ø¶¨ADSCµÄ¡£³ýÁËÓëMSC´ó²¿·Ö±êÖ¾Ïàͬ£¬¶øÇÒÓë³É
ÏËάϸ°û¸üÄÑÇø·Ö¡£ÒòΪ²»½öÔÚÐÎ̬ÏàËÆ£¬¶øÇÒ±íÃæÏ¸°û±êÖ¾¸üÊǽӽü[19]¡£Òò´Ë
µ¥´¿ÒÔϸ°û²»±í±êÖ¾À´¼ø¶¨ADSCÃ÷ÏÔ²»×ã¡£ÓÉÓÚ¼ä³äÖʸÉϸ°ûÓë³ÉÌåϸ°û×î´óµÄÇø
±ðÔÚÓÚËü¾ßÓÐÏò²»Í¬µÄ¼äÖÊ×éÖ¯Èç¹Ç¡¢Èí¹Ç¡¢¼¡Èâ¡¢¼¡ë죬֬·¾¡¢Éñ¾­¡¢Ñª¼°Ñª¹Ü
×éÖ¯¶àÏò·Ö»¯µÄÄÜÁ¦£¬Òò´Ë½øÐжàϵ¶¨ÏòÓÕµ¼Ö¤Ã÷ËüµÄ¶àÏò·Ö»¯ÄÜÁ¦¿ÉÄÜÊǽϺõÄ
¼ø¶¨¸Éϸ°ûµÄ·½·¨¡£²»Í¬Ñо¿ÒѾ­Ö¤Ã÷ƤÏÂÖ¬·¾×éÖ¯À´Ô´µÄ»ùÖÊϸ°ûͬMSCÒ»Ñù¾ßÓÐ
¶àϵ·Ö»¯µÄÄÜÁ¦¡£ÌåÍâÓÕµ¼Ñо¿Ö¤Ã÷£¬ÔÚרÃŵÄÓÕµ¼Òò×Ó´æÔÚµÄÌõ¼þÏ£¬ADSC¿ÉÒÔ
·Ö»¯ÎªÖ¬·¾Ï¸°û¡¢¹ÇºÍÈí¹Çϸ°û¡¢£¨ÐÄ£©¼¡Ï¸°û[6£¬7]¡£µ«ÓëMSCÏà±È£¬ADSC·Ö»¯Îª
Ö¬·¾Ï¸°ûµÄЧÂʸü¸ß£¬¶øMSC·Ö»¯Îª¹ÇºÍÈí¹Çϸ°ûµÄÄÜÁ¦¸ü¸ß[20]¡£ ÁíÍ⣬»¹¿ÉÒÔ
ÓÕµ¼·Ö»¯Îª¸Îϸ°û[21]¡¢Éñ¾­Ï¸°ûµÈ[22]¡£ÕâЩÑо¿ÎªADSCµÄ¹ã·ºÓ¦ÓÃÍØ¿íÁË»ù´¡
¡£

5  ADSC¿ÉÒÔ×÷ÓÃÓÐЧµÄ»ùÒòÔØÌåÓÃÓÚ»ùÒòÖÎÁÆ

      Ñо¿»¹·¢ÏÖ£¬ADSC¿ÉÒÔ×÷ΪÓÐЧµÄÖÎÁÆ»ùÒòÔØÌ壬ÓëMSC²»ÏàÉÏÏ¡£Ò»ÏîÑо¿
[23]±È½ÏÁËADSCÓëMSC¶Ô5ÐÍÏÙ²¡ËØ¡¢ÖÂÁöÄæ×ªÂ¼²¡¶¾¼°Âý²¡¶¾µÄתȾЧ¹û·¢ÏÖ£¬ÔÚ
MOIֵΪ14ʱÂý²¡¶¾¾Í¿ÉÒÔ»ñµÃ½Ï¸ßµÄתȾЧÂÊ(>90%)£¬ÊÇÖÂÁöÄæ×ªÂ¼²¡¶¾µÄ4ÖÁ5±¶
£¬¶øÇÒ²»Ó°Ïìϸ°ûµÄÉú³¤¡¢´«´úºÍ·Ö»¯¡£ÔÚÆäËüһЩÑо¿[24~26]ÖÐÔËÓÃÏÙ²¡¶¾×ªÈ¾
Ä¿µÄ»ùÒò¾ù»ñµÃÁ¼ºÃµÄЧ¹û¡£

6 ADSCµÄÅÔ·ÖÃÚ¹¦ÄÜ

      ADSC ¿ÉÒÔ·ÖÃÚ¾ßÓÐÉúÎï»îÐÔµÄVEGF¡¢HGF¡¢TGF-¦ÂµÈ¶àÖÖ´Ù½øÑª¹ÜÐÂÉúµÄÒò
×Ó[27£¬28]£¬ÔÚȱÑõÌõ¼þÏ£¬VEGF·ÖÃÚÃ÷ÏÔÔö¼Ó¸ß´ï5±¶¡£ÓÃȱÑõÌõ¼þϵÄADSCÅàÑø
ÉÏÇå¿ÉÒÔ¼ÓËÙÄÚÆ¤Ï¸°ûµÄÉú³¤£¬¼õÉÙÄÚÆ¤Ï¸°ûµÄµòÍö[28]¡£Hironori [13]µÈÓö¨Á¿
ʵʱPCR·ÖÎöµÄ·½·¨·¢ÏÖADSC³ýÁ˱í´ï½Ï¸ßˮƽµÄVEGF¡¢HGF¡¢TGF-¦¢Í⣬»¹¿ÉÒÔ¸ß
±í´ïPGF(placental growth factor),Öжȱí´ïFGF(fibroblast growth factor)-2
ºÍ Ang(angiopoietin)-1£¬µÍˮƽ±í´ïAng-2¡£

7 ADSCµÄÃâÒßµ÷½Ú×÷ÓÃ

      Í¬MSCÒ»Ñù£¬ADSCÒ²¾ßÓÐÃâÒßÑ¹ÖÆÐ§Ó¦£¬¿ÉÒÔµ÷½ÚÒÆÖ²ÎËÞÖ÷²¡£¨GVHD£©¡£
Puissant B[29] µÈ·¢ÏÖ£¬ÔÚÌåÍâADSC²»½ö²»»á¼¤»îͬÖÖÒìÌåµÄ·ÇÏàÈݵÄÁܰÍϸ°û£¬
¶øÇÒ¿ÉÒÔѹÒÖË¿ÁÑÔ­´Ì¼¤ºóµÄ»ìºÏÁܰÍϸ°û·´Ó¦£¨MLR£©ºÍÁܰÍϸ°ûÔöÖ³·´Ó¦£¬²¢ÇÒ
ÕâÖÖÒÖÖÆ×÷ÓóÊÖ¬·¾¸Éϸ°ûϸ°ûÊýÁ¿ÒÀÀµÐÔ£»ÕâÖÖ×÷ÓñØÐèÊÇÔÚÓëÁܰÍϸ°ûÓÐЧ½Ó
´¥µÄÌõ¼þÏ£¬ÈôÓÃͨ͸ÐÔĤ°ÑADSCÓëÁܰÍϸ°û¸ôÀ뿪£¬ÔòÒÖÖÆ×÷Óûá¼õÈõ¡£Ñо¿ÈÏ
ΪÕâÒ»×÷ÓÃÓëADSCµÄ·ÖÃÚ×÷ÓÃÎ޹ء£Yanez R[30]µÈͨ¹ý¶ÔСÊóGVHDµ÷½ÚµÄÑо¿·¢ÏÖ
£¬Ð¡ÊóºÍÈ˵ÄADSCµÄÃâÒßµ÷½ÚÌØµãÓëÈ˵ĹÇËèMSCÏàËÆ£»¶øÇÒÈ˵ÄADSC¿ÉÒÔÒÖÖÆÈËË¿
ÁÑÔ­ºÍÒìÌåTϸ°û´Ì¼¤ºóµÄǰÁܰÍϸ°ûµÄÔöÉúºÍϸ°ûÒò×ӵķÖÃÚ£»¸øÒÆÖ²°ëÏàºÏÔìѪ
¸Éϸ°ûµÄСÊóÊä×¢ADSC¿É¿ØÖÆÖÂËÀÐÔGVHDµÄ·¢Éú£¬¶øÓÐÑо¿[31]·¢ÏÖ¹ÇËèMSCÈ´²»ÄÜ
ÒÖÖÆÔÚÌåGVHD¡£ADSCµÄÕâÒ»×÷ÓÃÌØµãËÆºõ¿ÉÓÃÒìÌåÒÆÖ²ÎïµÄÃâÒßÅųâÖÎÁÆ¡£

8    רɫ֬·¾ÓëBATDCs

     Ö¬·¾×éÖ¯ÓÖ·ÖΪ°×ɫ֬·¾ºÍרɫ֬·¾£¬¶þÕßÔÚÉú³¤·¢ÓýÉÏ´æÔÚ»ùÒòµÄ²î±ð¡£°×
ɫ֬·¾Ö÷ÒªÓëÄÜÁ¿µÄÖü´æÓйأ¬¶ø×ØÉ«Ö¬·¾ÓëÄÜÁ¿µÄÏûºÄÓйØ[32]¡£Yamada YµÈ[3
3]´Óרɫ֬·¾ÖзÖÀë³öÀ´µÄ»ùÖÊϸ°û±»ÃüÃûΪBATDCs£¨brown adipose tissue der
ived cells£©£¬ÆäÖеÄCD29ÑôÐÔϸ°ûȺ±ÈMSCºÍÆêѪÀ´Ô´¸Éϸ°û¸üÈÝÒ×·Ö»¯ÎªÐļ¡¡£
ÔÚ¸ø¼±ÐÔÐĹ£´óÊóµÄ¹£ËÀÇøÐļ¡ÒÆÖ²CD29ÑôÐÔµÄBATDCºó£¬´óÊóµÄ¹£ÈûÃæ»ýºÍ×óÊÒÐÄ
¹¦ÄÜÁ½ÏîÖ¸±êµÄ¸ÄÉÆÏÔÖøÓÅÓÚ°×ɫ֬·¾ADSCϸ°ûÒÆÖ²×éºÍ¿Õ°×¶ÔÕÕ×é¡£Yamada YµÈ
½øÒ»²½Ñо¿[34]·¢ÏÖ£¬CD133ÑôÐÔµÄBATDCs±¾Éí²»½öÓнϸߵÄÐļ¡Ï¸°ûת»¯ÂÊ£¬¶øÇÒ
£¬ÕâÒ»×éϸ°û»¹¿ÉÒÔͨ¹ýÓë¹ÇËèÀ´Ô´MSC¹²ÅàÑøÊ±Ðγɶþ¼ÛÑôÀë×Ó¹²¼ÛÁª½ÓÀ´ÓÕµ¼¹Ç
ËèÀ´Ô´µÄMSCת»¯ÎªÐļ¡Ï¸°û¡£

9    ADSCµÄÓ¦ÓÃÕ¹Íû

       ADSC¿ÉÒÔ·Ö»¯Îª¶àϵ×é֯ϸ°û£¬Õâ¶ÔÓÚ×é֯ϸ°ûÌæ´úºÍÆ÷¹ÙÐÞ¸´ÖÎÁÆÊÇÊ®·Ö
ÓÐÒâÒåµÄ¡£Ñо¿·¢ÏÖADSCÔÚÌåÍâ¿ÉÒÔ·Ö»¯Îª×Ô·¢Ìø¶¯µÄÐļ¡Ï¸°û[35]£¬ÔÚÌå¿ÉÒÔת
»¯Îª¾ßÓÐÐļ¡Ï¸°û½á¹¹²¢ÓеçѹÒÀÀµÐԵĸÆÍ¨µÀºÍ¼ØÍ¨µÀ[36]£¬Òò´ËĿǰÑо¿ÓÃAD
SCÀ´ÖÎÁƼ±ÐÔÐĹ£ºÍÑÏÖØÐÄË¥¡£±¾ÊµÑéÊÒÔÚÇ°ÃæÑо¿[37]Öиø½áÔúǰ½µÖ§¶¯ÂöµÄÈ®
ÐĹ£Ä£ÐÍ»µËÀÖܱßÇøÐÄÄÚĤÏÂ×¢ÉäADSC£¬·¢ÏÖ¿ÉÃ÷ÏÔ¸ÄÉÆÐĹ£ºóÐŦÄÜ¡£¶ø³É¹Ç×÷
ÓÿÉÄÜÓÃÓÚ¹Ç÷ĵÄÔÙÉúºÍÐÞ¸´[36]£»ADSCµÄÅÔ·ÖÃÚ×÷Óÿɱ»ÓÃÀ´ÖÎÁÆÈ±ÑªÐÔ¼²²¡£º
ÓÐÑо¿[13£¬28]ÓÃADSCÖÎÁÆË«ÏÂ֫ȱѪ¶¯ÎïÄ£ÐÍÈ¡µÃÁ¼ºÃЧ¹û£¬¿ÉÏÔÖøÔö¼ÓȱѪÏÂ
Ö«µÄѪÁ÷Á¿¼°Ã«Ï¸Ñª¹ÜÃܶȡ£ADSCµÄ³ÉÖ¬×÷ÓÿÉÓÃÓÚÕûÐκÍÖØ½¨ÊÖÊõ[39]¡£ADSCµÄ
ÃâÒßÑ¹ÖÆÐ§Ó¦Ê¹µÃADSC¿ÉÒÔʵÐÐÒìÌåÒÆÖ²£¬Ìá¸ßÁËADSCÁÙ´²Ó¦ÓõĿɲÙ×÷ÐÔ£¬»¹¿É
ÒÔÔÚÆ÷¹ÙÒÆÖ²¿¹ÅÅÒì·´Ó¦Öз¢»Ó×÷Óá£ÁíÍ⣬ADSC¿ÉÒÔ×÷ΪÊʺϵĻùÒòÔØÌåΪ»ùÒò
ÖÎÁÆÌṩÁËеÄ;¾¶[40]¡£



×÷Õßµ¥Î»£º±±¾© 100853£¬½â·Å¾ü×ÜÒ½ÔºÐÄÄÚ¿Æ

×÷Õß¼ò½é£ºÇØÓîºì£¬ÄУ¬Ö÷ÖÎҽʦ£¬²©Ê¿Ñо¿Éú£¬Ñо¿·½Ïò£ºÐ£ËÀ¼°ÐÄÁ¦Ë¥½ß
µÄ¸Éϸ°ûÖÎÁÆ¡£

ÊÀ½ç¼±Î£Öز¡Ò½Ñ§ÔÓÖ¾2007£»4£¨3£©£º1889-1892
»Ø¸´´ËÂ¥
»¶Ó­¼ÓÈëÉúÎï²ÄÁÏQQȺ£º28451178
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hansom999

Òø³æ (СÓÐÃûÆø)

²Î¿¼ÎÄÏסª¡ª¿ÉÒÔÕÒµ½²»ÉÙ¾­µäÎÄÕÂ

1 Doss MX, Koehler CI, Gissel C, et al. Embryonic stem cells: a promisin
g tool for cell replacement therapy.J Cell Mol Med 2004 Oct-Dec;8(4):465
-473.

2 Siminiak T, Kalawski R, Fiszer D, et al. Autologous skeletal myoblast
transplantation for the treatment of postinfarction myocardial injury: p
hase I clinical study with 12 months of follow-up. Am Heart J 2004 Sep;1
48(3):531-537.

3 Zhang S, Jia Z, Ge J. Purified human bone marrow multipotent mesenchym
al stem cells regenerate infarcted myocardium in experimental rats. Cell
Transplant 2005;14(10):787-798.

4 van Laake LW, Hassink R, Doevendans PA, et al. Heart repair and stem c
ells. J Physiol 2006 Dec 1;577(Pt 2):467-478.

5 Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose
tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228
.

6 Zuk PA, Zhu M, Ashjian P,et al. Human adipose tissue is a source of mu
ltipotent stem cells. Mol Biol Cell 2002;13:4279-4295.

7 Ogawa R, Mizuno H, Watanabe A, et al. Osteogenic and chondrogenic diff
erentiation by adipose-derived stem cells harvested from GFP transgenic
mice. Biochem Biophys Res Commun. 2004 Jan 23;313(4):871-877.

8 Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of
murine and human adipose-derived stromal cells. Biochem Biophys Res Com
mun 2002 Jun 7;294(2):371-379.

9 Xu Y, Malladi P, Wagner DR, et al. Adipose-derived mesenchymal cells a
s a potential cell source for skeletal regeneration. Curr Opin Mol Ther
2005 Aug;7(4):300-305.

10 Lin TM, Tsai JL, Lin SD, et al. Accelerated growth and prolonged life
span of adipose tissue-derived human mesenchymal stem cells in a medium
using reduced calcium and antioxidants. Stem Cells Dev 2005 Feb;14(1):92
-102.

11 Guilak F, Awad HA, Fermor B, et al. Adipose-derived adult stem cells
for cartilage tissue engineering. Biorheology 2004;41(3-4):389-399.

12 Kiwaki K, Novak CM, Hsu DK, et al. Galectin-3 stimulates preadipocyte
proliferation and is up-regulated in growing adipose tissue.Obesity (Si
lver Spring) 2007 Jan;15(1):32-39.

13 Hironori Nakagami, Ryuichi Morishita,et al. Adipose Tissue-Derived St
romal Cells as a Novel Option for Regenerative Cell Therapy. Journal of
Atherosclerosis and Thrombosis 2006; 13 (2):77-81.

14 stem cells from adipose tissue, and differentiated cells from said ce
lls. US2004229351.

15 Gronthos S, Zannettino AC, Hay SJ, et al. Molecular and cellular char
acterisation of highly purified stromal stem cells derived from human bo
ne marrow.J Cell Sci 2003 May 1;116(Pt 9):1827-1835.

16 De Ugarte DA, Alfonso Z, Zuk PA, et al. Differential expression of st
em cell mobilization-associated molecules on multi-lineage cells from ad
ipose tissue and bone marrow.Immunol Lett 2003 Oct 31;89(2-3):267-270.

17 Seo MJ, Suh SY, Bae YC,et al. Differentiation of human adipose stroma
l cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res C
ommun. 2005 Mar 4;328(1):258-264.

18 Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human a
dipose lineage cells toward endothelial cells: physiological and therape
utic perspectives. Circulation 2004; 109:656-663.

19 Ishii M, Koike C, Igarashi A, et al. Molecular markers distinguish bo
ne marrow mesenchymal stem cells from fibroblasts[J].Biochem Biophys Res
Commun 2005 Jun 24;332(1):297-303.

20 Liu TM, Martina M, Hutmacher DW, et al. Identification of common path
ways mediating differentiation of bone marrow- and adipose tissue-derive
d human mesenchymal stem cells into three mesenchymal lineages. Stem Cel
ls 2007 Mar;25(3):750-760.

21 Seo MJ, Suh SY, Bae YC,et al. Differentiation of human adipose stroma
l cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res C
ommun 2005 Mar 4;328(1):258-264

22 Kokai LE, Rubin JP, Marra KG. The potential of adipose-derived adult
stem cells as a source of neuronal progenitor cells.Plast Reconstr Surg
2005 Oct;116(5):1453-1460.

23 Morizono K, De Ugarte DA, Zhu M, et al. Multilineage cells from adipo
se tissue as gene delivery vehicles. Hum Gene Ther 2003 Jan 1;14(1):59-6
6.

24 Zhang X, Yang M, Lin L, et al. Runx2 overexpression enhances osteobla
stic differentiation and mineralization in adipose--derived stem cells i
n vitro and in vivo.Calcif Tissue Int 2006 Sep;79(3):169-178.

25 Zheng PH, Wei FC, Jin GY, et al. Experimental studies of human adipos
e tissue-derived stromal cells transfected with ad-hBMP-2 gene. Hua Xi K
ou Qiang Yi Xue Za Zhi 2006 Jun;24(3):195-198.

26 Yamashiro H, Inamoto T, Yagi M, et al. Efficient proliferation and ad
ipose differentiation of human adipose  tissue-derived vascular stromal
cells transfected with basic fibroblast growth factor gene. Tissue Eng 2
003 Oct;9(5):881-892.

27 Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenker
k JE, Pell CL, Johnstone BH, Considine RV, and March KL: Secretion of an
giogenic and antiapoptotic factors by human adipose stromal cells. Circu
lation 2004; 109:1292-1298.

28 Nakagami H, Maeda K, Morishita R, et al. Novel autologous cell therap
y in ischemic limb disease through growth factor secretion by cultured a
dipose tissue-derived stromal cells . Arterioscler Thromb Vasc Biol. 200
5 Dec;25(12):2542-2547.

29 Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of hu
man adipose tissue-derived adult stem cells:comparison with bone marrow
mesenchymal stem cells. Br J Haematol 2005 Apr;129(1):118-129.

30 Yanez R, Lamana ML, Garcia-Castro J, et al. Adipose tissue-derived me
senchymal stem cells have in vivo immunosuppressive properties applicabl
e for the control of the graft-versus-host disease.Stem Cells 2006 Nov;2
4(11):2582-2591.

31 Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cel
ls suppress lymphocyte proliferation in vitro but fail to prevent graft-
versus-host disease in mice.J Immunol. 2006 Jun 15;176(12):7761-7.

32 Sudres M, Norol F, Trenado A,et al. Bone marrow mesenchymal stem cell
s suppress lymphocyte proliferation in vitro but fail to prevent graft-v
ersus-host disease in mice. J Immunol 2006 Jun 15;176(12):7761-7767.

33 Yamada Y, Wang XD, Yokoyama S, et al. Cardiac progenitor cells in bro
wn adipose tissue repaired damaged myocardium. Biochem Biophys Res Commu
n 2006 Apr 7;342(2):662-670.

34 Yamada Y, Yokoyama SI, Wang XD, et al.Cardiac stem cells in brown adi
pose tissue express CD133 and induce bone marrow non-hematopoietic cells
to differentiate into cardiomyocytes Stem. Cells  2007 Feb 8;1-2.

35 Planat-Benard V, Menard C, Andre M, et al. Spontaneous cardiomyocyte
differentiation from adipose tissue stroma cells.Circ Res 2004 Feb 6;94(
2):223-229.

36 Bai X, Pinkernell K, Song YH, et al. Genetically selected stem cells
from human adipose tissue express cardiac markers. Biochem Biophys Res C
ommun 2007 Feb 16;353(3):665-671.

37 ÏÄݼ£¬³Â¹â»Ô£¬Áõºê±óµÈ. Ö¬·¾¼äÆúÖʸÉϸ°ûÒÆÖ²¶ÔÈ®Ð£ËÀºóÐŦÄܵÄÓ°Ïì
. ÖйúÁÙ´²¿µ¸´2006; 10£¨45£©£º33-35.

38 Weinzierl K, Hemprich A, Frerich B. Bone engineering with adipose tis
sue derived stromal cells. J Craniomaxillofac Surg 2006 Dec;34(8):466-47
1.

39 Stosich MS, Mao JJ. Adipose tissue engineering from human adult stem
cells: clinical implications in plastic and reconstructive surgery. Plas
t Reconstr Surg 2007;119(1): 71-83.

40 Alpert JS. Are stem cells and genetic therapies ready for 'prime time
'? Am J Med 2007 Feb;120(2):103-104.
»¶Ó­¼ÓÈëÉúÎï²ÄÁÏQQȺ£º28451178
2Â¥2007-11-22 09:51:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
3Â¥2007-11-24 06:33:54
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ hansom999 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[˶²©¼ÒÔ°] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 8rmuugja8q 2026-02-22 7/350 2026-02-23 09:44 by w4l55oybr1
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 khieu8v8m0 2026-02-22 8/400 2026-02-23 09:35 by w4l55oybr1
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 8/400 2026-02-23 09:29 by w4l55oybr1
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +5 usprnugpzw 2026-02-21 11/550 2026-02-23 09:24 by w4l55oybr1
[½Ìʦ֮¼Ò] ΪʲôÖйú´óѧ¹¤¿Æ½ÌÊÚÃÇË®ÁËÄÇô¶àËùνµÄ¶¥»á¶¥¿¯£¬µ«»¹ÊÇ×ö²»³öÓîÊ÷»úÆ÷ÈË£¿ +5 »¶ÀÖËÌÒ¶Ýè 2026-02-21 8/400 2026-02-23 09:19 by »¶ÀÖËÌÒ¶Ýè
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 w89i99eaeh 2026-02-22 5/250 2026-02-23 08:04 by w4l55oybr1
[²©ºóÖ®¼Ò] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +6 3dfhjxgsh7 2026-02-22 9/450 2026-02-23 07:49 by w4l55oybr1
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 4/200 2026-02-23 06:46 by jsjzfl
[˶²©¼ÒÔ°] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 8/400 2026-02-23 06:24 by w4l55oybr1
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +5 3dfhjxgsh7 2026-02-22 6/300 2026-02-23 02:04 by 5jlh3qtdvx
[½Ìʦ֮¼Ò] °æÃæ·Ñ¸Ã½»Âð +7 Æ»¹ûÔÚÄÄÀï 2026-02-22 8/400 2026-02-22 22:37 by otani
[»ù½ðÉêÇë] »ù½ðÕýÎÄ30Ò³Ö¸µÄÊDZ¨¸æÕýÎÄ»¹ÊÇÕû¸öÉêÇëÊé +5 successhe 2026-02-16 6/300 2026-02-22 21:38 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[»ù½ðÉêÇë] ÃæÉÏ¿ÉÒÔ³¬¹ý30Ò³°É£¿ +4 °¢À­¹±aragon 2026-02-22 4/200 2026-02-22 21:22 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 usprnugpzw 2026-02-21 6/300 2026-02-22 19:48 by w89i99eaeh
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 3dfhjxgsh7 2026-02-22 4/200 2026-02-22 16:52 by khieu8v8m0
[ÕÒ¹¤×÷] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-22 3/150 2026-02-22 16:37 by khieu8v8m0
[¹«Åɳö¹ú] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-21 4/200 2026-02-22 16:27 by khieu8v8m0
[»ù½ðÉêÇë] ¡°ÈËÎÄÉç¿Æ¶øÂÛ£¬Ðí¶àѧÊõÑо¿»¹Ã»ÓдﵽÃñ¹úʱÆÚµÄˮƽ¡± +4 ËÕ¶«ÆÂ¶þÊÀ 2026-02-18 5/250 2026-02-22 16:07 by liangep1573
[»ù½ðÉêÇë] ½ñÄê´ºÍíÓм¸¸ö½ÚÄ¿ºÜ²»´í£¬µãÔÞ£¡ +11 ˲ϢÓîÖæ 2026-02-16 12/600 2026-02-21 21:14 by lq493392203
[»ù½ðÉêÇë] ÌåÖÆÄÚ³¤±²ËµÌåÖÆÄÚ¾ø´ó²¿·ÖÒ»±²×ÓÔڵײ㣬ÈçͬÄãÃÇÒ»Ñù´ó²¿·ÖÆÕͨ½ÌʦæÇÒÊÕÈëµÍ +9 ˲ϢÓîÖæ 2026-02-20 12/600 2026-02-21 10:39 by »¶ÀÖËÌÒ¶Ýè
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û